Skip to main content

Day: March 26, 2024

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed biotech industry executive Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer – WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) —  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress. “Among...

Continue reading

Mobilicom Reports 2023 Year-End Financial Results

SHOHAM, Israel, March 26, 2024 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced financial results for the year ended December 31, 2023. Recent Operational Highlights:Received initial production-scale order in Q3 2023 followed by additional quantity-increase order in Q4 2023 from U.S. Tier-1 drone manufacturer which delivers to the U.S. Department of Defense (“DOD”) Chosen by the U.S.DOD for Soldiers’ Next Generation Wearable Tactical AI-Enhanced Mission Kits Secured $900,000 initial production-scale order from global Tier-1 Israeli-based manufacturer for loitering (kamikaze) drones platform Secured initial production-scale order from another global Tier-1 Israeli-based manufacturer for use by the...

Continue reading

DSV, 1098 – SHARE BUYBACK IN DSV A/S

Company Announcement No. 1098 On 1 February 2024, we initiated a share buyback programme, as described in Company Announcement No. 1087. According to the programme, the company will in the period from 1 February 2024 until 23 April 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.78% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back   Average transaction price Amount DKK           Accumulated trading...

Continue reading

TransUnion Announces Earnings Release Date for First Quarter 2024 Results

CHICAGO, March 26, 2024 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) will publish its financial results for the first quarter ended March 31, 2024, in a press release to be issued at approximately 6:00 a.m. Central Time (CT) on Thursday, April 25, 2024. The company will hold a conference call on the same day at 8:30 a.m. Central Time (CT) to discuss its financial results. The press release and a live webcast of the earnings conference call will be available on the TransUnion Investor Relations website at http://www.transunion.com/tru. About TransUnion (NYSE: TRU) TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable...

Continue reading

Bahr Transportation Transforms Operations with Descartes’ Transportation Management, Freight Visibility and Capacity Sourcing Solutions

ATLANTA and LONDON, March 26, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Charlotte, NC-based Bahr Transportation, a freight brokerage specializing in the movement of perishable goods across the U.S. and Canada, is using the cloud-based Descartes Aljex™ transportation management system (TMS), together with Descartes MacroPoint™ real-time transportation visibility platform (RTTVP) and automated capacity sourcing solutions. The integrated solutions allow Bahr Transportation to cover more customer freight while providing full visibility across the supply chain to enhance shipper and carrier relationships. “We specialize in refrigerated shipments of temperature-sensitive perishable goods, which means we...

Continue reading

e.GO Announces Nasdaq Delisting Notice

AACHEN, Germany, March 26, 2024 (GLOBE NEWSWIRE) — Next.e.GO N.V. (NASDAQ:EGOX) (“e.GO”) today announced that on March 25, 2024 the Company received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities because the Company’s securities have had a closing bid price below $0.10 for ten consecutive trading days, which triggers a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). In addition to the $0.10 Rule delisting notice, the Company also currently fails to satisfy the requirement that the closing bid price of its securities remain at $1.00 or higher as required by Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price...

Continue reading

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Data readout from Phase 3 clinical trial in the People’s Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreement with GNI Cash and cash equivalents totaled $33.5 million as of December 31, 2023 SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced financial results for...

Continue reading

Parsons Continues US Air Force Research and Development Support Through $28 Million Task Order

CHANTILLY, Va., March 26, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a $28 million cost-plus-fixed-fee contract to provide intelligence, surveillance, and reconnaissance command and control and space software baselines for the Air Force Research Laboratory’s (AFRL) Global Application Research, Development, Engineering, and Maintenance (GARDEM) program. The contract includes one three-year performance period and extends Parsons’ portfolio of work supporting the Department of Defense (DOD) and Intelligence Community (IC), delivering exquisite software capabilities across the all-domain battlespace. “Parsons delivers value for national security customers like the U.S. Air Force by integrating technologies, transforming data, and customizing site-specific capabilities to meet...

Continue reading

UTStarcom Announces Changes to Its Board of Directors

HANGZHOU, China, March 26, 2024 (GLOBE NEWSWIRE) — UTStarcom (“UT” or the “Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today announced changes to the Board of Directors and appointed Dr. Yong Wang as the Company’s new independent director, effective Mar 21, 2024. Dr. Jintong Lin resigned from the Company’s board of Directors, as well as the chairman of the Company’s Nominating and Corporate Governance Committee, member of Audit Committee and Compensation Committee on Mar 21, 2024, which he had held since September 2019. Dr. Yong Wang was appointed as an independent director of the Company and the positions in various committees vacated by Dr. Lin, effective Mar 21, 2024. Mr. Ning Shan, UTStarcom’s Chairman of Board of Directors, commented, “On behalf of the Company and the board of directors, we...

Continue reading

Valeura Energy Inc.: Fourth Quarter and Year-end 2023 Results

Record Results in 2023 from First Year of Thailand Operations SINGAPORE and CALGARY, Alberta, March 26, 2024 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”), the upstream oil and gas company with assets in the Gulf of Thailand and the Thrace Basin of Türkiye, reports its financial and operating results for the three month period and year ended December 31, 2023. The complete reporting package for the Company, including the audited financial statements and associated management’s discussion and analysis (“MD&A”) and the 2023 annual information form (“AIF”), are being filed on SEDAR+ at www.sedarplus.ca and posted to the Company’s website at www.valeuraenergy.com.     2023 HighlightsClosed the Mubadala Acquisition(1) for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.